Form 4: Director Jonathan Knowles Increases Stake in Caris Life

Director Jonathan Knowles acquired 1,600 shares of Caris Life Sciences, Inc. as part of his 2026 board retainer compensation.

Summary

• Director Jonathan Knowles acquired 1,600 shares of common stock on May 29, 2026.
• The shares were issued at a price of $15.62 per share.
• The acquisition represents compensation in lieu of cash for 2026 board retainer fees.
• Following this transaction, the director's total beneficial ownership is 308,979 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Director demonstrates alignment with shareholders by accepting equity in lieu of cash compensation.
• Increased insider ownership often signals confidence in the company's long-term prospects.

Negatives

• None identified; this is a standard compensatory transaction.

Risks

• None identified; this is a standard compensatory transaction.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that it is common practice for directors in the life sciences and biotech sectors to receive a portion of their board compensation in equity to preserve cash for R&D and clinical trials.

Comparison to Industry Standards

• The practice of issuing shares in lieu of cash for board retainers is a standard corporate governance mechanism to align director interests with those of shareholders.
• The valuation methodology using a ten-day volume-weighted average price (VWAP) is consistent with standard market practices for equity-based compensation.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensatory issuance.

Key Dates

Keywords

Caris Life Sciences, CAI, Insider Trading, Form 4, Director Compensation, Equity Ownership